TRDA touts EEV platform safety and less frequent dosing for DMD
TRDA’s conference update said its EEV platform showed strong safety, enhanced delivery and less frequent dosing for DMD therapies, alongside early functional and biomarker data. It cited upcoming clinical readouts and robust financial position for accelerated approval plans.
The conference highlighted the EEV platform’s strong safety profile, improved delivery and less frequent dosing for DMD therapies, alongside promising early functional and biomarker data. Upcoming clinical readouts and a strong financial position are supporting accelerated approval plans, while the Vertex partnership remains in place.